Infographic: The port delivery system with ranibizumab for neovascular age-related macular degeneration: LADDER trial
- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Campochiaro, P. A., Marcus, D. M., Awh, C.C. et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder
clinical trial. Ophthalmology, 126(8), 1141–1154.
All authors equally contributed to the conceptualisation and creation of the visual abstract.
SS reported receiving financial support from AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Pharmaceuticals, Janssen Pharmaceuticals, Nova
Nordisk, Optos, Ocular Therapeutics, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics, Sanofi. SS is Editor in Chief of Eye. IB & CH declare no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Anyone you share the following link with will be able to read this content: